nanofibrillar cellulose as a lyoprotective matrix in the ... · nanofibrillar cellulose as a...

1
Nanofibrillar cellulose as a Lyoprotective Matrix in The Freeze-Drying of HepG2 Liver Cancer Cells INTRODUCTION Freeze-drying of complex human cells has yielded insufficient viabilities due to the lack of compatible lyoprotective matrices [1]. The usage of nanofibrillar cellulose (NFC) as a lyoprotective matrix is not defined in previous literature. The aim of this thesis is to study the effects of NFC when it is freeze-dried and recreated while carrying 3D cell spheroid systems. OBJECTIVES We have evaluated the capabilities of NFC as a lyoprotective matrix in the freeze-drying process of HepG2 cells under sterile conditions. The highest viability was reached trough optimization of the process itself and testing of most suitable compounds for cryo- and lyopreservation (5). METHODS A human liver carcinoma cell line HepG2 was cultivated in a mixture of NFC and medium (1) and then freeze-dried and stored in controlled conditions (3). Simultaneously, HepG2 control samples without NFC were freeze-dried and stored in corresponding manner. After rehydration, the viability of both sample types was measured (4) and the mitochondrial activity evaluated. In addition, the morphology of the cells during each step was analyzed (2, 6). RESULTS Results demonstrate that without the protective NFC matrix the HepG2 cells could not survive the freeze-drying process. However, when protected by the NFC matrix, the cells gained noticeable viability when rehydrated. CONCLUSIONS Nanofibrillar cellulose appears to be a promising candidate as a lyoprotective matrix in the freeze-drying of human cells. The preserved viability during the freeze-drying could lead to the development of new cell products for research and clinical applications in the future. Vili-Veli Auvinen 1 , Arto Merivaara 1 , Raili Koivuniemi 1 , Heli Paukkonen 1 , Patrick Laurén 1 , Timo Laaksonen* 1,2 , Marjo Yliperttula* 1 1 Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland 2 Department of Chemistry and Bioengineering, Tampere University of Technology, P.O. Box 541, FI-33101 Tampere, Finland * Corresponding author HELSINGIN YLIOPISTO HELSINGFORS UNIVERSITET UNIVERSITY OF HELSINKI FARMASIAN TIEDEKUNTA FARMACEUTISKA FAKULTETEN FACULTY OF PHARMACY ACKNOWLEDGEMENTS This work was funded by the University of Helsinki. The authors acknowledge the Drug Discovery and Chemical Biology Network and Institute of Biotechnology, funded by Biocenter Finland, for providing access to screening instrumentation, and the Helsinki Electron microscopy unit at the Institute of Biotechnology, University of Helsinki, for the electron microscopy. Tekes, Finnish Center for Innovation, is acknowledged via the University driven 3D-Nano-MiniT Tekes project and UPM-Kymmene Oyj is acknowledged for providing the nanofibrillated cellulose for the Tekes- project and the present study. RESULTS 1. 2. 3. 4. 5. References [1] Wikström, J. (2013). Alginate-based microencapsulation and lyophilization of human retinal pigment epithelial cell line (ARPE- 19) for cell therapy. Optimization of Lyoprotectants PEG 6000 (0.7 wt.%) Trehalose (0.3 wt.%) Glycerol (1 wt.%) Viability (Calcein intensity) GrowDex® 0.8 wt.% & 24h trehal. incub. x x x ++ GrowDex® 0.8 wt.% & 24h trehal. incub. x x + GrowDex® 0.8 wt.% & 24h trehal. incub. x + GrowDex® 0.8 wt.% & 24h trehal. incub. x ++ GrowDex® 0.8 wt.% & 24h trehal. incub. x x ++ GrowDex® 0.8 wt.% & 24h trehal. incub. + GrowDex® 0.4 wt.% & 24h trehal. incub. x x x +++ GrowDex® 0.4 wt.% & 24h trehal. incub. x x ++ GrowDex® 0.4 wt.% & 24h trehal. incub. x ++ GrowDex® 0.4 wt.% & 24h trehal. incub. x ++ GrowDex® 0.4 wt.% & 24h trehal. incub. x x +++ GrowDex® 0.4 wt.% & 24h trehal. incub. ++ GrowDex® 0.8 wt.% x x + GrowDex® 0.8 wt.% x + GrowDex® 0.8 wt.% + Without GrowDex® x x Without GrowDex® x x Without GrowDex® x Without GrowDex® & 24h treha. Incub. x x Without GrowDex® & 24h treha. Incub. x x Without GrowDex® & 24h treha. Incub. x 6. Day 5 HepG2 spheroids before freeze-drying Live Dead After freeze-drying and rehydration

Upload: trinhphuc

Post on 10-Nov-2018

221 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Nanofibrillar cellulose as a Lyoprotective Matrix in The ... · Nanofibrillar cellulose as a Lyoprotective Matrix in The Freeze-Drying of HepG2 Liver Cancer Cells INTRODUCTION Freeze-drying

Nanofibrillar cellulose as a Lyoprotective

Matrix in The Freeze-Drying of HepG2

Liver Cancer Cells

INTRODUCTION

Freeze-drying of complex human cells has yielded insufficient viabilities dueto the lack of compatible lyoprotective matrices [1]. The usage ofnanofibrillar cellulose (NFC) as a lyoprotective matrix is not defined inprevious literature. The aim of this thesis is to study the effects of NFC whenit is freeze-dried and recreated while carrying 3D cell spheroid systems.

OBJECTIVES

We have evaluated the capabilities of NFC as a lyoprotective matrix in thefreeze-drying process of HepG2 cells under sterile conditions. The highestviability was reached trough optimization of the process itself and testing ofmost suitable compounds for cryo- and lyopreservation (5).

METHODS

A human liver carcinoma cell line HepG2 was cultivated in a mixture of NFCand medium (1) and then freeze-dried and stored in controlled conditions(3). Simultaneously, HepG2 control samples without NFC were freeze-driedand stored in corresponding manner. After rehydration, the viability of bothsample types was measured (4) and the mitochondrial activity evaluated. Inaddition, the morphology of the cells during each step was analyzed (2, 6).

RESULTS

Results demonstrate that without the protective NFC matrix the HepG2 cellscould not survive the freeze-drying process. However, when protected by theNFC matrix, the cells gained noticeable viability when rehydrated.

CONCLUSIONS

Nanofibrillar cellulose appears to be a promising candidate as alyoprotective matrix in the freeze-drying of human cells. The preservedviability during the freeze-drying could lead to the development of new cellproducts for research and clinical applications in the future.

Vili-Veli Auvinen1,

Arto Merivaara1,

Raili Koivuniemi1,

Heli Paukkonen1,

Patrick Laurén1,

Timo Laaksonen*1,2,

Marjo Yliperttula*1

1 Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland

2 Department of Chemistry and Bioengineering, Tampere University of Technology, P.O. Box 541, FI-33101 Tampere, Finland

* Corresponding author

HELSINGIN YLIOPISTO

HELSINGFORS UNIVERSITET

UNIVERSITY OF HELSINKI

FARMASIAN TIEDEKUNTA

FARMACEUTISKA FAKULTETEN

FACULTY OF PHARMACY

ACKNOWLEDGEMENTS

This work was funded by the University of Helsinki. The authorsacknowledge the Drug Discovery and Chemical Biology Network andInstitute of Biotechnology, funded by Biocenter Finland, for providing accessto screening instrumentation, and the Helsinki Electron microscopy unit atthe Institute of Biotechnology, University of Helsinki, for the electronmicroscopy. Tekes, Finnish Center for Innovation, is acknowledged via theUniversity driven 3D-Nano-MiniT Tekes project and UPM-Kymmene Oyj isacknowledged for providing the nanofibrillated cellulose for the Tekes-project and the present study.

RESULTS

1. 2. 3.

4. 5.

References

[1] Wikström, J. (2013). Alginate-based microencapsulation and lyophilization of human retinal pigment epithelial cell line (ARPE-19) for cell therapy.

Optimization of Lyoprotectants

PEG 6000 (0.7 wt.%)

Trehalose(0.3 wt.%)

Glycerol (1 wt.%)

Viability (Calcein intensity)

GrowDex® 0.8 wt.% & 24h trehal. incub. x x x ++

GrowDex® 0.8 wt.% & 24h trehal. incub. x x +

GrowDex® 0.8 wt.% & 24h trehal. incub. x +GrowDex® 0.8 wt.% & 24h trehal. incub. x ++GrowDex® 0.8 wt.% & 24h trehal. incub. x x ++GrowDex® 0.8 wt.% & 24h trehal. incub. +

GrowDex® 0.4 wt.% & 24h trehal. incub. x x x +++

GrowDex® 0.4 wt.% & 24h trehal. incub. x x ++

GrowDex® 0.4 wt.% & 24h trehal. incub. x ++GrowDex® 0.4 wt.% & 24h trehal. incub. x ++GrowDex® 0.4 wt.% & 24h trehal. incub. x x +++GrowDex® 0.4 wt.% & 24h trehal. incub. ++GrowDex® 0.8 wt.% x x +GrowDex® 0.8 wt.% x +GrowDex® 0.8 wt.% +Without GrowDex® x xWithout GrowDex® x xWithout GrowDex® xWithout GrowDex® & 24h treha. Incub. x xWithout GrowDex® & 24h treha. Incub. x xWithout GrowDex® & 24h treha. Incub. x

6.

Day 5 HepG2 spheroids before freeze-drying

Live Dead After freeze-drying and rehydration